| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | NEUTRAL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.65▲ | 1.64▲ | 1.63▲ | 1.63▲ | 1.79▼ |
| MA10 | 1.63▲ | 1.63▲ | 1.62▲ | 1.65▲ | 1.98▼ |
| MA20 | 1.63▲ | 1.62▲ | 1.63▲ | 1.75▼ | 2.11▼ |
| MA50 | 1.66▲ | 1.65▲ | 1.70▼ | 2.00▼ | 1.22▲ |
| MA100 | 1.73▼ | 1.84▼ | 1.90▼ | 2.11▼ | 1.03▲ |
| MA200 | 1.93▼ | 2.04▼ | 2.04▼ | 1.35▲ | 1.53▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.009▲ | 0.009▲ | 0.011▲ | 0.008▲ | -0.135▼ |
| RSI | 59.761▲ | 55.920▲ | 53.021▲ | 43.143▼ | 48.327▼ |
| STOCH | 62.917 | 56.984 | 62.500 | 22.240 | 13.401▼ |
| WILL %R | 0.000▲ | 0.000▲ | 0.000▲ | -72.143 | -84.829▼ |
| CCI | 165.990▲ | 202.880▲ | 186.667▲ | 8.263 | -155.144▼ |
|
Thursday, November 06, 2025 07:00 AM
Net loss: The Company reported a net loss of $3.9 million, or $0.85 per basic and diluted common share, for the three months ended September 30, 2025, compared with a net loss of $7.1 million, or ...
|
|
IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site
Wednesday, October 29, 2025 01:00 AM
NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune ...
|
|
Monday, October 27, 2025 08:50 AM
IN8bio (INAB) presented new preclinical data from its gammadelta T cell engager program, INB-619, at the 2025 American College of Rheumatology, ACR, Convergence Meeting in Chicago. In preclinical SLE ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 21/11/25 | 1.62 | 1.7499 | 1.5603 | 1.70 | 49,578 |
| 20/11/25 | 1.68 | 1.7299 | 1.59 | 1.59 | 77,242 |
| 19/11/25 | 1.64 | 1.6516 | 1.60 | 1.62 | 34,912 |
| 18/11/25 | 1.62 | 1.6696 | 1.575 | 1.64 | 73,355 |
| 17/11/25 | 1.59 | 1.72 | 1.5801 | 1.59 | 36,747 |
| 14/11/25 | 1.59 | 1.70 | 1.59 | 1.59 | 43,283 |
| 13/11/25 | 1.67 | 1.77 | 1.6236 | 1.64 | 60,805 |
| 12/11/25 | 1.67 | 1.70 | 1.64 | 1.70 | 27,982 |
| 11/11/25 | 1.72 | 1.89 | 1.66 | 1.68 | 54,606 |
| 10/11/25 | 1.61 | 1.80 | 1.56 | 1.72 | 84,929 |
|
|
||||
|
|
||||
|
|